🌟 RESTORING THE GUT MICROBIOME, ONE THERAPEUTIC AT A TIME 🌟 At BiomeBank, we’re proud to collaborate with world-leading researchers like Associate Professor Sam Forster and his team at the Hudson Institute of Medical Research to develop the next generation of microbiome therapies. 💡 Why the microbiome matters Our gut microbiome holds the key to our health. As Assoc. Prof. Forster explains, “The microbes we carry are intimately associated with our health,” playing a crucial role in regulating our immune response and maintaining balance in our bodies. 🔬 Science at the forefront The Australian Microbiome Culture Collection—founded by A/Prof Forster—contains over 40,000 bacterial isolates, enabling targeted research and the development of groundbreaking therapies. Together, BiomeBank and Hudson are leveraging this vast collection to create cultured microbiome therapies that target specific diseases. 🚀 Pioneering progress BiomeBank has already made history with the world’s first approved donor-derived microbiome therapy for C. Difficile infection. Now, we’re evolving toward cultured therapies—produced under controlled conditions in bioreactors, offering scalable, precision-based solutions for patients. 🤝 Our mission We’re restoring the gut microbiome to transform lives with therapies that reflect the best science globally. 📢 Follow us for updates Stay tuned as we continue to translate cutting-edge research into life-changing therapies. Follow us for updates on our progress, and if you’re an investor or collaborator interested in advancing this transformative field, we’d love to connect! 💬 Let us know your thoughts or share this post to amplify our mission! Thanks Australian Health Journal for sharing our story. #GutMicrobiome #Microbiome #Biotech #Therapeutics #Innovation #GutHealth #LifeSciences #InvestInScience #HudsonInstitute #BiomeBank #ResearchToTherapy #GlobalHealth Sam Costello | Christopher Hall | Paul Flynn | Stephanie Morris | Nancy Briefs | Johnathon Matthews | Justin Green | Jo Close | Megan Polidano |
DEVELOPING THE NEXT GENERATION OF MEDICINES THAT TARGET AND ENHANCE THE MICROBIOME Groundwork laid for a future of cultured microbiome therapies targeting specific diseases INTERVIEW Associate Professor Sam Forster, CSL Centenary Fellow, Research Group Head Microbiota and Systems Biology, Hudson Institute of Medical Research & Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank Dr Sam Costello, Co-founder & CEO BiomeBank SEGMENT Filmed in Melbourne & Adelaide | December 2024 Assoc Prof Forster describes the role of the microbiome, “Every one of us carries thousands of bacteria. Millions of individual cells, and they're intimately associated with all sorts of sites on our bodies. So our gut is the most common place we think about, but our lungs, our skin, everywhere. Where there's an interface, the external environment, there's bacteria and other microbes that actually enable us to interface with the external world. They detect changes and they regulate our immune response.” “The microbes we carry are intimately associated with our health.”, says Assoc Prof Forster. He was the founder of the Australian Microbiome Culture Collection at Hudson that now contains over 40,000 bacterial isolates. This provides a resource for further research. “All of these opportunities are available because we have this vast collection of microbes where we can say this particular combination for you is relevant for this experiment. Taking clinical samples, we then can replicate the host environment using microfluidic organ on-a-chip systems”, says Assoc Prof Forster. The Hudson Institute of Medical Research and BiomeBank have partnered to advance microbiome-based therapeutics. Their collaboration focuses on identifying key bacteria involved in disease onset and resolution, particularly associated with the gut. By combining their expertise, they aim to develop targeted microbial therapies to treat and prevent diseases by restoring gut microbial ecology. BiomeBank develops and delivers microbiome therapies. In 2022 BiomeBank was successful in introducing the world's first approved donor derived microbiome therapy approved in Australia for the treatment of C. Difficile infection. Through this collaboration, the Hudson Institute and BiomeBank are at the forefront of microbiome research, striving to translate scientific discoveries into effective therapies that can improve patient outcomes. As Dr Costello states, “We see microbiome therapies evolving in the next few years from predominantly donor derived therapies that are harvested from screened healthy stool donors, towards cultured therapies that can be grown in bioreactors and produced under controlled conditions.”